Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Small Cell Lung Carcinoma 2

Interventions

Carboplatin 25Etoposide 23Cisplatin 16pembrolizumab 9Topotecan 9atezolizumab 7Pemetrexed 7Nivolumab 7Radiosurgery 6Irinotecan 5durvalumab 4Paclitaxel 4Gemcitabine 4Albumin-Bound Paclitaxel 4rovalpituzumab tesirine 3etoposide phosphate 3Radiotherapy 3Magnetic Resonance Spectroscopy 3Ipilimumab 3Cyclophosphamide 3vistusertib 2roniciclib 2pelcitoclax 2pazopanib 2epacadostat 2amrubicin 2Vorinostat 2Radiation 2Fluorodeoxyglucose F18 2Doxorubicin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Small Cell Lung Carcinoma × roniciclib × Clear all
NCT01573338 2021-04-08

Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 When Given Together With Chemotherapy and the Effectiveness of This Combination Treatment in Shrinking a Specific Type of Lung Tumors (Small Cell Lung Cancer)

Bayer

Phase 1/2 Terminated
43 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT02161419 2018-06-25

CONCEPT-SCLC

Bayer

Phase 2 Terminated
142 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡